Boston Scientific Welcomes FDA Panel Recommendation to Approve Promus / Xience V Everolimus-eluting Coronary Stent System

NATICK, Mass., November 29, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the recommendation of a U.S. Food and Drug Administration (FDA) advisory panel to approve with conditions the PROMUS(TM) / XIENCE(TM) V...

Comments

• Find It

• Recently Written

  • test post
  • Type 2 Diabetes And Obesity Research - ZenBio, Inc. Awarded $1.38…
  • Fact Sheets About Thyroid Disorders Published By NIDDK
  • Genentech Issues Dear Healthcare Provider Letter Regarding A Reported …
  • Behavioral Modification Programs Help Obese Children Manage Their Weight
  • Loss of the protein target of lithium disrupts normal mouse embryonic heart development
  • Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien Study
  • FDA: No Lou Gehrig’s disease risk with statins
  • Repurposing Of Enbrel For Alzheimer’s Disease
  • Researchers Propose Minocycline As A Promising Drug For Patients With Fragile X Syndrome

• Categories

  • News

• Monthly Archives

  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • December 1969

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • FDA MedWatch
  • Health Canada RSS
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2008 Drug Injury News